Capivasertib is currently in Phase III development as a combination therapy for breast (ER + BC and TNBC) and prostate cancers, including patients with mutations in PI3K/AKT/PTEN pathway genes [11, 13, 15, 16]. This evidence concerns the gene AKT1 and breast cancer.